The pathophysiology, medical management and dental implications of adult attention-deficit/hyperactivity disorder

Journal of the American Dental Association

Volumn 138, Issue 4, 2007, Pages 475-482

  Friedlander, Arthur H ^a,b   Yagiela, John A ^b,c   Mahler, Michael E ^a,c   Rubin, Robert ^a,c  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Attention; Attention deficit hyperactivity disorder; Dental care for disabled; Drug interactions

Indexed keywords

EID: 34247510318     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2007.0199     Document Type: Article

References (75)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington: American Psychiatric Association; 1994:85-93.
2. Seidman LJ, Doyle A, Fried R, Valera E, Crum K, Matthews L. Neuropsychological function in adults with attention-defitit/hyperactivity disorder. Psychiatr Clin North Am 2004;27(2):261-82.
3. Adler L, Cohen J. Diagnosig and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27(2):187-201.
4. Berkley RA. Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27(2):233-60.
5. Wender PH, Wolf LE, Wasserstein J. Adults with ADHD: an overview. Ann N Y Acad Sci 2001;931:1-16.
6. Brown TE. Brown attention-deficit disorder scales. San Antonio: Psychological Corp.; 1996.
7. Conners CK, Erhardt D, Sparrow E. Conners' adult ADHD rating scales: Technical manual. North Tonawanda, N.Y.: Multi-Health Systems; 1999.
8. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993;150(6):885-90.
9. Murphy KB, Adler LA. Assessing attention-deficit/hyperactivity disorder in adults: focus on rating scales. J Clin Psychiatry 2004;65(supplement 3): 12-7.
10. Adler LA. Clinical presentations of adult patients with ADHD. J Clin Psychiatry 2004;65(supplement 3):8-11.
11. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 2006;45(2):192-202.
12. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163(4):716-23.
13. Faraone SV, Spencer TJ, Montano CB, Biederman J. Attention-deficit/ hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care. Arch Intern Med 2004;164(11):1221-6.
14. Biederman J, Faraone SV, Monuteaux MC, Bober M, Cadogen E. Gender effects on attention-deflcit/hyperactivity disorder in adults, revisited. Biol Psychiatry 2004;56(7):692-700.
15. Murphy K, Barkley RA. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Atten Disord 1996;1(3):147-61.
16. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993;60(7):565-76.
17. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53(2):112-20.
18. Wilens TE, Biederman J, Spencer TJ. Attention deficit/hyperactivity disorder across the lifespan. Annu Rev Med 2002;53:113-31.
19. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63(supplement 12):10-5.
20. Spencer TJ, Biederman J, Wilens TE, Faraone SV. Overview and neurobiology of attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63(supplement 12):3-9.
21. Heiligenstein E, Conyers LM, Berns AR, Miller MA. Preliminary normative data on DSM-IV attention deficit hyperactivity disorder in college students (published correction appears in J Am Coll Health 1998;46[5]:213). J Am Coll Health 1998;46(4):185-8.
22. Hervey AS, Epstein JN, Curry JF. Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review. Neuropsychology 2004;18(3):485-503.
23. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry 1996;37(6):393-401.
24. Brod M, Johnston J, Able S, Swindle R. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life Scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res 2006;15(1): 117-29.
25. Kates N. Attention deficit disorder in adults: management in primary care. Can Fam Physician 2005;51:53-9.
26. Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year followup study. Psychol Med 2006;36(2): 167-79.
27. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993;150(12):1792-8.
28. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995;152(11):1652-8.
29. Wilens TE. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry 2004;65(supplement 3):38-45.
30. Faraone SV. Genetics of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27(2):303-21.
31. Biederman J, Faraone SV, Mick E, et al. High risk for attention deficit hyperactivity disorder among children of parents with childhood onset of the disorder: a pilot study. Am J Psychiatry 1995;152(3):431-5.
32. Lanau F, Zenner MT, Civelli O, Hartman DS. Epinephrine and norepinephrine act as potent agonists at the recombinant human dopamine D, receptor. J Neurochem 1997;68(2):804-12.
33. Larisch R, Sitte W, Antke C, et al. Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder. Nucl Med Commun 2006;27(3):267-70.
34. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005;57(11):1215-20.
35. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord 2002;5(4);189-202.
36. Seidman LJ, Valera EM, Makris N. Structural brain imaging of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57(11):1263-72.
37. Hesslinger B, Tebartz van Elst L, Thiel T, Haegele K, Hennig J, Ebert D. Frontoorbital volume reductions in adult patients with attention deficit hyperactivity disorder. Neurosci Lett 2002;328(3):319-21.
38. Zametkin AJ, Nordahl TE, Gross M, et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med 1990;323(20):1361-6.
39. Schweitzer JB, Lee DO, Hanford RB, et al. Effect of methylphenidate on executive functioning in adults with attentiondeficit/hyperactivity disorder: normalization of behavior but not related brain activity. Biol Psychiatry 2004;56(8):597-606.
40. Roth RM, Saykin AJ. Executive dysfunction in attention-deficit/ hyperactivity disorder: cognitive and neuroimaging findings. Psychiatr Clin North Am 2004;27(1):83-96.
41. Riordan HJ, Flashman LA, Saykin AJ, Frutiger SA, Carroll KE, Huey L. Neuropsychological correlates of methylphenidate treatment in adult ADHD with and without depression. Arch Clin Neuropsychol 1999;14(2):217-33.
42. Wilens TE. Drug therapy for adults with attention-deficit hyperactivity disorder. Drugs 2003;63(22):2395-411.
43. Wilens TE, Faraone SV, Biederman J. Attention-deficit/hyperactivity disorder in adults. JAMA 2004;292(6):619-23.
44. Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol 2002;22(5):468-73.
45. Spencer TJ. ADHD treatment across the life cycle. J Clin Psychiatry 2004;65(supplement 3):22-6.
46. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53(2):112-20.
47. Himpel S, Banaschewski T, Heise CA, Rothenberger A. The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder. Expert Opin Drug Saf 2005;4(2):311-21.
48. Wilens TE, Biederman J, Mick E, Spencer TJ. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis 1995;183(1):48-50.
49. Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996:153(9):1147-53.
50. Davise WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L. Bupropion sustained release in adolescents with comorbid attention-deficit/ hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 2001;40(3):307-14.
51. Wilens TE, Prince JB, Spencer T, et al. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biol Psychiatry 2003;54(1):9-16.
52. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005;57(7):793-801.
53. Safren SA, Sprich S, Chulvick S, Otto MW. Psychosocial treatments for adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27(2):349-60.
54. Murphy K. Psychosocial treatments for ADHD in teens and adults: a practice-friendly review. J Clin Psychol 2005;61(5):607-19.
55. Kalbag AS, Levin FR. Adult ADHD and substance abuse: diagnostic and treatment issues. Subst Use Misuse 2005;40(13-14):1955-81, 2043-8.
56. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR, 4th ed, text revision. Washington: American Psychiatric Association; 2000:89.
57. Barkley RA, Murphy KR, O'Connell T, Connor DF. Effects of two doses of methylphenidate on simulator driving performance in adults with attention deficit hyperactivity disorder. J Safety Res 2005;36(2):121-31.
58. Potter AS, Newhouse PA. Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 2004;176(2):182-94.
59. Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry 2005;62(10):1142-7.
60. Xu J, Mendrek A, Cohen MS, et al. Brain activity in cigarette smokers performing a working memory task: effect of smoking abstinence (published correction appears in Biol Psychiatry 2006;60[2]:204). Biol Psychiatry 2005;58(2):143-50.
61. Grossi 8G, Genco RJ, Machtei EE, et al. Assessment of risk for periodontal disease, II: risk indicators for alveolar bone loss. J Periodontol 1995;66(1):23-9.
62. Montano B. Diagnosis and treatment of ADHD in adults in primary care. J Clin Psychiatry 2004;65(eupplement 3):18-21.
63. Smith AP. Caffeine at work. Hum Psychopharmacol 2005;20(6):441-5.
64. Bagheri R, Burrow MF, Tyas M. Influence of food-simulating solutions and surface finish on susceptibility to staining of aesthetic restorative materials. J Dent 2005;33(5):389-98.
65. Heller KE, Hurt BA, Eklund SA. Sugared soda consumption and dental caries in the United States. J Dent Res 2001;80(10):1949-53.
66. Physicians' desk reference 2006. 60th ed. Montvale, N.J.: Thomson PDR; 2006.
67. McEvoy GK. AHFS Drug information 2006. Bethesda, Md.: American Society of Health-System Pharmacists; 2006.
68. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57(5):456-63.
69. Adler LA, Spencer TJ, Milton DR, Moore RJ, Michelson D. Longterm, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry 2005;66(3):294-9.
70. Gage TW, Pickett FA. Mosby's dental drug reference. 6th ed. St. Louis: Mosby; 2003.
71. Callahan AM, Marangell LB, Ketter TA. Evaluating the clinical significance of drug interactions: a systematic approach. Harv Rev Psychiatry 1996;4(3):153-8.
72. Haas DA. Adverse drug interactions in dental practice: interactions associated with analgesics - part III in a series. JADA 1999;130(3):397-407.
73. Ganzberg S. Psychoactive drugs. In: Ciancio SG, ed. ADA guide to dental therapeutics. 3rd ed. Chicago: American Dental Association; 2003:382-411.
74. Yagiela JA. Adverse drug interactions in dental practice: interactions associated with vasoconstrictors - part V of a series. JADA 1999;130(5):701-9.
75. Broquet KE. Status of treatment of depression. South Med J 1999;92(9):846-56.